Skip to main
LMAT

LeMaitre Vascular (LMAT) Stock Forecast & Price Target

LeMaitre Vascular (LMAT) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

LeMaitre Vascular Inc reported significant financial growth, with operating income increasing by 47% year-over-year to $18.8 million and adjusted gross margin improving to 70.4%, indicating strong operational efficiency. The company's organic revenue for full-year 2025 grew by 14%, driven by both price and volume increases, along with a notable regional sales surge in EMEA (+29%) and APAC (+20%). Additionally, strong demand in the Americas, along with emerging opportunities in the Chinese market which experienced 24% growth, further supports a positive outlook for the company's future performance.

Bears say

LeMaitre Vascular Inc. may face significant challenges due to potential technical issues with its mRidium pump, unexpected competition, and regulatory hurdles that could adversely affect financial performance. The company is at risk from lower price increases, competitive pressures, slower international adoption, and potential delays in regulatory approvals, which could negatively impact revenue growth expectations. Additionally, the discrepancy between forecasted and actual revenues, alongside the possibility of reduced reimbursement rates for procedures, further underscores the fundamental risks that could lead to a decline in the company's share value.

LeMaitre Vascular (LMAT) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LeMaitre Vascular (LMAT) Forecast

Analysts have given LeMaitre Vascular (LMAT) a Buy based on their latest research and market trends.

According to 5 analysts, LeMaitre Vascular (LMAT) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LeMaitre Vascular (LMAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.